

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7222751

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	MEDIMMUNE, LLC	02/25/2022
RECEIVING PARTY DATA		
Name:	MEDIMMUNE LIMITED	
Street Address:	MILSTEIN BUILDING, GRANTA PARK	
City:	CAMBRIDGE	
State/Country:	UNITED KINGDOM	
Postal Code:	CB216GH	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	17528378
CORRESPONDENCE DATA		
Fax Number:	(301)398-9306	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	3013980000	
Email:	patents@astrazeneca.com	
Correspondent Name:	ASTRAZENECA	
Address Line 1:	ONE MEDIMMUNE WAY	
Address Line 4:	GAITHERSBURG, MARYLAND 20878	
ATTORNEY DOCKET NUMBER:	RLX2-100-US-DIV	
NAME OF SUBMITTER:	KIM NOROOZI	
SIGNATURE:	/Kim Noroozi/	
DATE SIGNED:	03/14/2022	
Total Attachments: 3		
source=executed_Medi LLC to Medi LTD#page1.tif		
source=executed_Medi LLC to Medi LTD#page2.tif		
source=executed_Medi LLC to Medi LTD#page3.tif		

ASSIGNMENT OF PATENT RIGHTS

THIS ASSIGNMENT is made as of the 18 February 2022 (the "**Effective Date**") by and between

MEDIMMUNE, LLC, a limited liability company formed under the laws of the State of Delaware under no. 2130616, whose post office address is One MedImmune Way, Gaithersburg, Maryland 20878, the United States of America ("**Assignor**"); and

MEDIMMUNE LIMITED, a company incorporated in England and Wales under no. 2451177, whose registered office is Milstein Building, Granta Park, Cambridge, CB21 6GH, United Kingdom ("**Assignee**").

WHEREAS, Assignor has agreed to assign to Assignee the Assignor's entire right, title and interest in and to the patent applications identified in the attached Schedule (the "**Applications**") and in and to the inventions and improvements disclosed in such Applications.

NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:

1. For good and valuable consideration made by Assignee to Assignor, receipt of which is hereby acknowledged, the Assignor hereby assigns, with full title guarantee, free from all and any charges or other third party rights, to Assignee absolutely their entire right, title and interest in and to the inventions, the Applications and any patents or applications derived therefrom; any divisions, continuations and continuations-in-part thereof; any re-issues, re-examinations, or extensions thereof; all rights to claim priority on the basis of the Applications and any patents or applications derived therefrom; and the right to file patent applications derived from the Applications directly in the name of Assignee or an affiliated company of Assignee (in countries or regions where such filings are permissible) (collectively, the "**Rights**"), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Assignor acknowledges that Assignee shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and Assignor waives any right of first refusal that they may have for acquiring such Rights.
2. Assignor agrees with Assignee that their assignment to Assignee includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Rights, including all rights to recover damages, profits and injunctive relief for infringement of any of the Rights.
3. Assignor agrees with Assignee that they shall, at the expense of Assignee, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by Assignee to enable Assignee or its successors, nominees or assigns to:
 - a) secure the vesting of the Rights in Assignee or in its successors, nominees or assigns;
 - b) defeat any challenge to the validity of and resolve any questions concerning the Rights; and
 - c) apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Rights, including the right to claim convention priority from such Patents and including, without limitation, cooperating in any proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.
4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

5. This assignment shall be governed by and construed in accordance with the laws of England and Wales and the parties hereby submit to the exclusive jurisdiction of the English courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.



Signed for and on behalf of
MEDIMMUNE, LLC

Name: **Patrick Scott Alban**

Title: Authorised Signatory

Date February 25, 2022



Signed for and on behalf of
MEDIMMUNE LIMITED

Name: **Mark Ness**

Title: Authorised Signatory

Date 02-MARCH-2022

THE SCHEDULE

APPLICATIONS				
AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
RLX2-100-CN-PCT	China	National	201880008499.7	24 January 2018
RLX2-100-EP-EPT	Europe	National	18702944.2	24 January 2018
RLX2-100-HK-FPR	Hong Kong	National	62020008132.6	24 January 2018
RLX2-100-JP-PCT	Japan	National	2019-538362	24 January 2018
RLX2-100-WO-PCT	International	PCT	PCT/EP2018/051757	24 January 2018
RLX2-100-US-PCT	USA	National	16/480,568	17 November 2021
RLX2-100-US-DIV	USA	National	17/528,378	24 January 2018

Priority Applications

AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
RLX2-100-US-PSP	USA	Provisional	62/450,338	25 Jan 2017